Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response aligns strongly with the provided FDA label content for the congestive heart failure/ fluid retention boxed warning and related warning (Sections 5.1 and Boxed Warning), without contradictions. Some included generic/brand statements are not part of the supplied label excerpts and are therefore outside scope but not contradicted.
Category Scores
Accurate Statements
Pioglitazone/ACTOS can cause fluid retention and fluid retention may lead to or exacerbate congestive heart failure.
Boxed Warning and Section 5.1: “cause or exacerbate congestive heart failure” and “can cause dose-related fluid retention… may lead to or exacerbate congestive heart failure.”
Patients should be observed/monitored for signs and symptoms of congestive heart failure and managed according to standards of care if it develops, with discontinuation or dose reduction to be considered.
Section 5.1 and Boxed Warning language in the provided excerpts.
Pioglitazone/ACTOS should be used with caution in patients at risk for congestive heart failure and in patients with edema.
Section 5.5 Edema: “ACTOS should be used with caution in patients with edema” and “used with caution in patients at risk for congestive heart failure… monitored.”
ACTOS is contraindicated for initiation in patients with established NYHA Class III or IV heart failure.
Section 4 Contraindications: “Initiation in patients with established NYHA Class III or IV heart failure [see Boxed Warning].”
Unsupported Statements
Generic pioglitazone is the off-patent version of the brand drug pioglitazone.
Not supported or addressed in the supplied prescribing information excerpts.
Generic pioglitazone is used to treat type 2 diabetes.
The provided label excerpts do not include indications.
In most cases, a generic drug has the same active ingredient (pioglitazone) as the reference product.
Not supported or addressed in the supplied prescribing information excerpts.
A generic drug is designed to work the same way as the reference product.
Not supported or addressed in the supplied prescribing information excerpts.
Differences between generic and brand drugs can occur in non-active ingredients and the pill’s appearance.
Not supported or addressed in the supplied prescribing information excerpts.
Contradictions
Important Omissions
The AI response does not explicitly mention that ACTOS is not recommended in patients with symptomatic heart failure (as stated in the Boxed Warning excerpt).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core safety claim (that thiazolidinediones/ACTOS can cause or exacerbate congestive heart failure via fluid retention) is directly supported by the Boxed Warning and Section 5.1. One boxed-warning element (not recommended in symptomatic heart failure) is omitted but not contradicted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Additional label nuance from the Boxed Warning (not recommended in symptomatic heart failure) was not included.
Suggested Improvement
Include the Boxed Warning statement that ACTOS is not recommended in patients with symptomatic heart failure, alongside the CHF/fluid retention monitoring and contraindication for NYHA III/IV initiation.